Filtered By:
Condition: Heart Failure
Nutrition: Sodium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 255 results found since Jan 2013.
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research
Differential Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes According to Renal Function: A Dose-Response Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals
CONCLUSION: The protective effects of SGLT2i for reducing most adverse cardiovascular and renal outcomes persisted in patients with variable degrees of renal impairment. The observed benefits such as preventing CV death, HF worsening, or stroke may be greater for patients with more severe CKD. Considering the cardiovascular and renal benefits associated with SGLT2i treatment, patients with CKD should be treated aggressively to improve outcomes.PROSPERO REGISTRATION NUMBER: CRD42021273500.PMID:37474112 | DOI:10.1093/ejendo/lvad078
Source: European Journal of Endocrinology - July 20, 2023 Category: Endocrinology Authors: Donna Shu-Han Lin An-Li Yu Hao-Yun Lo Cheng-Wei Lien Jen-Kuang Lee Fu-Tien Chiang Yu-Kang Tu Source Type: research
Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
ConclusionIn patients with type 2 diabetes, the hypotensive effects of SGLT2i and GLP-1 RAs were significantly associated with a reduction in mortality and cardiorenal events. These findings suggest that the lowering BP effect could be seen as an additive indicator of cardiovascular protection by SGLT2i and GLP-1 RAs drugs.
Source: Acta Diabetologica - July 13, 2023 Category: Endocrinology Source Type: research
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with
advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of
dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was
associated with significantly lower rate of MACE and mortality. The study results
reinforced the benefits of sodium bicarbonate therapy in the expanding CKD
population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research
Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research
